Institutional members access full text with Ovid®

Share this article on:

Oral antiretroviral chemoprophylaxis: current status

Baeten, Jared; Celum, Connie

Current Opinion in HIV and AIDS: November 2012 - Volume 7 - Issue 6 - p 514–519
doi: 10.1097/COH.0b013e3283582d30

Purpose of review Preexposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use oral antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention strategy.

Recent findings During the past 2 years, proof-of-concept that PrEP protects against sexual HIV acquisition has been demonstrated in three clinical trials, conducted among MSM and heterosexual men and women. These trials used daily oral tenofovir disoproxil fumarate, alone or coformulated with emtricitabine. The degree of HIV protection in these trials was strongly related to the level of adherence to PrEP. Two additional clinical trials, both among heterosexual women, did not demonstrate HIV protection with PrEP, with low adherence to daily use of PrEP the leading hypothesis for lack of efficacy; adherence and biologic mechanisms for lack of efficacy in these trial populations are being evaluated.

Summary Oral chemoprophylaxis, using tenofovir and combination emtricitabinetenofovir, is effective for prevention of sexual HIV transmission. Next steps in the field include rigorous evaluation of uptake and adherence to PrEP in implementation settings.

Departments of Global Health, Medicine, and Epidemiology University of Washington, Seattle, Washington, USA

Correspondence to Jared Baeten, MD, PhD, Department of Global Health, International Clinical Research Center, University of Washington, Box 359927, 325 Ninth Avenue, Seattle, WA 98104, USA. Tel: +1 206 520 3808; e-mail:

© 2012 Lippincott Williams & Wilkins, Inc.